The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

There were 262,063.05 new cases, 2,742,285.75 prevalence, 115,973.98 deaths, and 2,260,975.34 DALYs of breast cancer among older adults in 2021 in Asia. From 1990 to 2021, the ASRs of breast cancer ...

Despite significant improvements in survival of patients with multiple myeloma (MM), outcomes remain heterogeneous, and a significant proportion of patients experience suboptimal outcomes. Importantly ...

Background: Optimal first line therapy for patients with metastatic melanoma is an immunotherapy regimen containing an anti-PD1 antibody, regardless of tumour BRAF mutation status. Anti-PD1 antibodies ...

Background: NIVO + RELA fixed-dose combination (FDC), compared with NIVO alone, demonstrated a clinically meaningful benefit to progression-free survival (HR 0.79, 95% CI 0.66–0.95) and overall ...

Between February 2023 and July 2024, we enrolled 125 of 174 approached caregivers (71.8%). Participants assigned to the BMT-CARE App used the app for a median of 146.9 minutes (range, 0-384.8). At day ...

The purpose of this guideline is to update the ASCO evidence-based recommendations on the use of sentinel lymph node biopsy (SLNB) in early-stage breast cancer. ASCO first published a practice ...

Exacerbating these concerns, trial-related nonmedical costs may disproportionately affect lower socioeconomic status populations. A 2017 analysis of 1,600 cancer clinical trial participants found that ...

Approximately 6,600 new cases of ALL and 1,300 deaths related to ALL were reported in the United States in 2024. 1 The incidence of ALL decreases with age; 25% of patients are age 20-60 years, and 11% ...

Recruitment for LCS programs faces numerous challenges, including socioeconomic, cultural, logistical, and racial disparities. Current LCS guidelines often fail to address differences in sex, smoking ...

The Pediatric Holistic Evaluation of Auditory Risk (PedsHEAR) model architecture used several machine learning approaches followed by an ensemble predictor. The primary end point was post-treatment ...

Despite several randomized controlled trials demonstrating the benefits of combination therapies for metastatic hormone-sensitive prostate cancer (mHSPC), a significant treatment gap persists. This ...